Shehab, A;
Todorova, A;
Ahmed, A;
Gonzalez-Lopez, E;
Knebel, F;
Alibazoglu, H;
Sabbour, H;
... Shah, NR; + view all
(2022)
Pearls from the First Gulf Cardiac Amyloidosis Summit 2021.
New Emirates Medical Journal
, 3
(1)
pp. 1-11.
10.2174/03666220117152535.
Preview |
PDF
001NEMJ.pdf - Published Version Download (4MB) | Preview |
Abstract
These proceedings from the First Gulf Cardiac Amyloidosis Summit held in June 2021 aimed to increase awareness of cardiac amyloidosis among the wider medical community in the region. Although the clinical presentation of cardiac amyloidosis is highly variable, a number of 'red flags' have been identified to raise suspicion of the disease and prompt further investigation. Accurate diagnosis of cardiac amyloidosis is challenging and relies on the integration of clinical, imaging and laboratory investigations. Recent imaging techniques, including bone scintigraphy together with a complete serum and urine workup, allow, in the majority of patients, accurate non-invasive diagnosis without the need for confirmatory endomyocardial biopsies. Early differential diagnosis between light-chain (AL) amyloidosis and transthyretin amyloidosis (ATTR) is critical for timely delivery of appropriate therapy. AL amyloidosis is a medical emergency requiring chemotherapy and supportive care. Treatment for ATTR-amyloidosis is most effective when administered early, before development of significant symptoms or cardiac dysfunction. Optimal management of patients involves close collaboration between multidisciplinary specialists, which may include hematologists, cardiologists, and other subspecialists, ideally at a designated specialty center with interest and expertise in amyloidosis.
| Type: | Article |
|---|---|
| Title: | Pearls from the First Gulf Cardiac Amyloidosis Summit 2021 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2174/03666220117152535 |
| Publisher version: | http://dx.doi.org/10.2174/03666220117152535 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Amyloidosis, Transthyretin, Diagnosis, Cardiomyopathy, Scintigraphy, Genetic testing. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10210562 |
Archive Staff Only
 |
View Item |
